New immune combo aims to stall pancreatic cancer in 100 patients
NCT ID NCT07199764
First seen Sep 30, 2025 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This study tests a two-drug immunotherapy (odetiglucan and mitazalimab) as a maintenance treatment for people with advanced pancreatic cancer that has not worsened after initial chemotherapy. The goal is to see if this combination can delay cancer growth for at least 7.5 months. About 100 adults whose cancer is locally advanced or spread will receive the treatment, and researchers will monitor safety and how long the cancer stays controlled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.